Form D · Other Health Care
IMPEL NEUROPHARMA INC
Seattle, WA · CIK 0001445499
Offering snapshot reported Apr 1, 2021 · SEC filing
- Reported sold
- $0 Offering amount: $1.93M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 18, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 1, 2021 | Initial | $0 | No comparison | 1 | SEC filing |
| Mar 12, 2021 | Initial | $7,500,000 | No comparison | 8 | SEC filing |
| Feb 17, 2021 | Initial | $0 | No comparison | 2 | SEC filing |
| May 6, 2020 | Initial | $0 | No comparison | 1 | SEC filing |
| Jan 30, 2020 | Initial | $0 | No comparison | 1 | SEC filing |
| Jul 3, 2019 | Initial | $0 | No comparison | 1 | SEC filing |
| Feb 22, 2019 | Initial | $0 | No comparison | 4 | SEC filing |
| Dec 1, 2016 | Initial | $22,297,064 | No comparison | 10 | SEC filing |
| Oct 18, 2016 | Initial | $80,000 | No comparison | 1 | SEC filing |
| Aug 29, 2016 | Initial | $1,090,000 | No comparison | 4 | SEC filing |
| Sep 18, 2015 | Initial | $4,000,000 | No comparison | 1 | SEC filing |
| Sep 14, 2015 | Initial | $1,257,927 | No comparison | 21 | SEC filing |
| Nov 27, 2013 | Initial | $2,640,025 | No comparison | 19 | SEC filing |
| Aug 10, 2012 | Initial | $25,000 | No comparison | 1 | SEC filing |
| Sep 20, 2011 | Initial | $527,329 | No comparison | 8 | SEC filing |
| Jan 21, 2010 | Initial | $305,364 | No comparison | 7 | SEC filing |
| Sep 15, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-394399
Represents securities offered under an equity incentive plan.
Source: Form D, filed Apr 1, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Adrian Adams | Director, Executive |
| David Allison | Director |
| Jon Congleton | Director, Executive |
| Michael Hite | Director |
| Rodney Ho | Director |
| John D. Hoekman | Director, Executive |
| John Leaman | Executive |
| Robert Mittendorff | Director |
| Tim Nelson | Director |
| Stewart Parker | Director |
| Aaron Royston | Director |
| Ali Satvat | Director |
| Mahendra Shah | Director |
| Diane Wilfong | Director |
| Jim Young | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
201 Elliott Ave. W Suite 260
Seattle, WA, 98119
Seattle, WA, 98119